CRMD - CorMedix, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.5300
-0.0500 (-3.16%)
At close: 4:00PM EDT

1.5699 +0.04 (2.61%)
After hours: 5:09PM EDT

Stock chart is not supported by your current browser
Previous Close1.5800
Open1.5800
Bid1.5200 x 1000
Ask1.6000 x 3000
Day's Range1.5000 - 1.6050
52 Week Range0.1700 - 2.7400
Volume2,860,269
Avg. Volume2,857,708
Market Cap181.925M
Beta (3Y Monthly)3.31
PE Ratio (TTM)N/A
EPS (TTM)-0.3010
Earnings DateMar 18, 2019 - Mar 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • ACCESSWIRE6 days ago

    CorMedix Inc. Reports Fourth Quarter And Full-Year 2018 Financial Results, Announces Reverse Stock Split And Provides Business Update

    Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 14, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing ...

  • ACCESSWIRE9 days ago

    CorMedix Inc. to Present at Roth and Oppenheimer & Co. Investor Conferences

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 11, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know
    Zacks9 days ago

    Will CorMedix (CRMD) Report Negative Q4 Earnings? What You Should Know

    CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ACCESSWIRE13 days ago

    CorMedix Inc. to Report Year Ended December 31, 2018 Financial Results on Thursday, March 14

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 7, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

  • ACCESSWIRE16 days ago

    CorMedix Inc. Appoints Alan W. Dunton, M.D. to Board of Directors

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 4, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Alan W. Dunton, M.D. has been appointed unanimously to the Company's Board of Directors. Dr. Dunton becomes the sixth member of the Company's Board, filling a vacant seat previously occupied by Gary Gelbfish, M.D., who resigned in January 2019. Khoso Baluch, CorMedix Chief Executive Officer stated, "I am excited to have Alan join the board of CorMedix.

  • GlobeNewswire27 days ago

    Research Report Identifies SS&C Technologies, Allergan plc, CorMedix, The Allstate, Vedanta, and Lexicon Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Feb. 21, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE28 days ago

    Biotech Bounce Just Getting Started

    HENDERSON, NV / ACCESSWIRE / February 20, 2019 / Biotech may have had a hard 2018, but the sector is making up for lost time at the start of this year. This may be just getting started as many fund managers ...

  • Here's Why CorMedix Dropped as Much as 27.1% Today
    Motley Foollast month

    Here's Why CorMedix Dropped as Much as 27.1% Today

    The company announced an update after meeting the FDA.

  • ACCESSWIRElast month

    CorMedix Inc. Announces FDA Meeting Update

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / February 14, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has begun discussions with the U.S. FDA regarding its recently completed and unblinded Phase 3 LOCK-IT-100 study to support regulatory approval for Neutrolin®, the Company's investigational product under development as a catheter lock solution for patients suffering from end stage renal disease undergoing hemodialysis. At the meeting, the FDA agreed that the Company could request consideration of Neutrolin for approval under the LPAD (Limited Population Pathway for Antibacterial and Antifungal Drugs) pathway. Data originally submitted to the FDA included preliminary analyses from 653 subjects at the time of the interim analysis, including the first 28 cases of catheter-related blood stream infection (CRBSI).

  • ACCESSWIRElast month

    Biotech and Cannabis Stocks That Are Emerging

    HENDERSON, NV / ACCESSWIRE / February 13, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX) , a life sciences company focused on stem cell-based therapies, is developing ...

  • ACCESSWIRElast month

    These Healthcare Stocks Could Surpass Investor Expectations

    Companies working in the healthcare sector are tasked with meeting the growing demand for effective treatment options given that, almost every day, medical experts discover a new disease or ailment. Premier Health Group (OTC:PHGRF) (CSE:PHGI), CAS Medical Systems Inc (CASM), CorMedix Inc (NYSE American: CRMD), and Viking Therapeutics Inc (VKTX) represent four healthcare companies determined to create products to help consumers have a better life.

  • ACCESSWIRE2 months ago

    Cormedix Inc. Announces Topline Analysis of the Full Data Set of Phase 3 Lock-It-100 Study Reinforces the Interim Results

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 30, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the topline results of the full data set of the Company's Phase 3 LOCK-IT-100 study for Neutrolin® as a catheter lock solution in hemodialysis patients. The Company recently announced the topline results from the interim analysis of the study, which was terminated in August 2018 following the recommendation of the independent Data Safety Monitoring Board (DSMB), because efficacy had been demonstrated and the pre-specified level of statistical significance had been achieved. Efficacy data were available from 653 subjects at the time of the interim analysis, including the first 28 cases of catheter-related blood stream infection (CRBSI).

  • GlobeNewswire2 months ago

    Factors of Influence in 2019, Key Indicators and Opportunity within The Hain Celestial Group, Allegheny Technologies, NVR, Greif, CorMedix, and Enzo Biochem — New Research Emphasizes Economic Growth

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Options Traders Expect Huge Moves in CorMedix (CRMD) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in CorMedix (CRMD) Stock

    Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.

  • ACCESSWIRE2 months ago

    These 4 Healthcare Stocks Are Raising Expectations

    With the rise of global population, coupled with depletion of most common resources, consumer access to healthcare is crucial to securing the health and wellness of all living people, resulting in a need for companies in the space to meet these demands. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), LM Funding America Inc., (LMFA), CorMedix Inc (CRMD), and ContraFect Corp (CFRX) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.

  • ACCESSWIRE2 months ago

    Cormedix Inc. Announces Highly Statistically Significant Topline Results For Neutrolin(R) From The Interim Analysis Of The Phase 3 Lock-It-100 Study

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 17, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the topline results of the interim analysis of the Company's Phase 3 LOCK-IT-100 study for Neutrolin® as a catheter lock solution in hemodialysis patients. As previously announced, the study was terminated at the recommendation of the independent Data Safety Monitoring Board (DSMB) after the interim analysis was completed in July 2018, because efficacy had been demonstrated and the pre-specified level of statistical significance had been achieved.

  • ACCESSWIRE2 months ago

    CorMedix Inc. Announces Resignation of Member of Its Board of Directors

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 16, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that Gary A. Gelbfish, MD FACS has resigned his position as a member of the Board of Directors, effective January 14, 2019.Dr. Gelbfish's most recent tenure on the board began in August 2017.He previously served on CorMedix's Board from December 2009 to June 2014, including a term as Board Chairman from 2012 to June 2014. Khoso Baluch, CorMedix Chief Executive Officer and a member of the Board stated, "We thank Gary for his service and guidance during the LOCK-IT-100 study.He provided significant insight that contributed to its successful completion.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Incyte and CorMedix

    NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...

  • ACCESSWIRE2 months ago

    This Stock Generated 25X Returns In Just Five Years: Could BTCY Be At The Same Crossroads?

    The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few subsectors have benefitted more than remote cardiac care. Companies like Biotelemetry (BEAT) have grown by leaps and bounds in the last few years as their proprietary remote cardiac monitoring devices have gained traction.

  • ACCESSWIRE2 months ago

    Cormedix Announces Closing of $7.5 Million Senior Secured Convertible Debt Financing

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / January 3, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has closed and drawn a previously announced $7.5 million, senior secured convertible debt financing with its largest shareholder. At the investor's option, the loan is convertible into the Company's common stock at a price equal to $1.50 per share. Additionally, the loan will automatically convert at the conversion rate into shares of common stock, if, prior to the maturity date, the average closing sale price of the Company's common stock for any 20 trading days during any consecutive 30 trading days equals or exceeds 150% of the conversion price.

  • Implied Volatility Surging for CorMedix (CRMD) Stock Options
    Zacks3 months ago

    Implied Volatility Surging for CorMedix (CRMD) Stock Options

    Investors need to pay close attention to CorMedix (CRMD) stock based on the movements in the options market lately.

  • ACCESSWIRE3 months ago

    CBD and Biotech Plays on The Rise

    HENDERSON, NV / ACCESSWIRE / December 11, 2018 / We have found several companies releasing recent news we believe should be on your radar. Today we are highlighting: Delcath Systems, Inc. (DCTH), KushCo ...

  • ACCESSWIRE3 months ago

    Cormedix Receives Approval to Sell $5.4 Million of NOL Tax Benefits Through the New Jersey Economic Development Authority Program

    BERKELEY HEIGHTS, NJ / ACCESSWIRE / December 10, 2018 / CorMedix Inc. (CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the New Jersey Economic Development Authority (NJEDA) has approved the Company's application to participate in the New Jersey Technology Business Tax Certificate Transfer (NOL) program for State Fiscal Year 2018. The approval will allow CorMedix to transfer approximately $5.4 million of the total $6.1 million in available tax benefits to an unrelated, profitable New Jersey corporation in return for approximately $5.0 million in cash, which is anticipated by the end of 2018. Closing is subject to NJEDA's typical closing conditions, which are in process.

  • ACCESSWIRE4 months ago

    Biomedical Trends Fuel New Momentum For Healthcare Stocks; Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Alliqua BioMedical, BioScrip, Coremedix

    CORAL GABLES, FL / ACCESSWIRE / November 28, 2018 / Healthcare stocks and biotechnology stocks have rallied during recent quarters. New developments in technology and drug therapies have boosted excitement within the market. Premier Health Group, Inc. (PHGRF) (PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education.

  • GlobeNewswire4 months ago

    Consolidated Research: 2018 Summary Expectations for Kadmon, Overstock, AECOM, Steelcase, CorMedix, and Corindus Vascular Robotics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.